Loading…

Variable Bcl-2 phenotype in benign and malignant lesions of urothelium

We examined Bcl-2, Bax and p53 expression in transitional epithelium, benign lesions derived from transitional epithelium (Brunn's nests and inverted papillomas) and transitional cell cancer (TCC) of the upper urinary tract and urinary bladder using immunostaining of cryostat sections. We also...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 1998-06, Vol.128 (1), p.87-92
Main Authors: Bilim, Vladimir N, Tomita, Yoshihiko, Kawasaki, Takashi, Takeda, Masayuki, Takahashi, Kota
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c420t-1a257e4725af3174cf45b691e3f15be1f93b3460f0f15e5415aba27d6c2a0ff33
cites cdi_FETCH-LOGICAL-c420t-1a257e4725af3174cf45b691e3f15be1f93b3460f0f15e5415aba27d6c2a0ff33
container_end_page 92
container_issue 1
container_start_page 87
container_title Cancer letters
container_volume 128
creator Bilim, Vladimir N
Tomita, Yoshihiko
Kawasaki, Takashi
Takeda, Masayuki
Takahashi, Kota
description We examined Bcl-2, Bax and p53 expression in transitional epithelium, benign lesions derived from transitional epithelium (Brunn's nests and inverted papillomas) and transitional cell cancer (TCC) of the upper urinary tract and urinary bladder using immunostaining of cryostat sections. We also performed Western blot analysis of normal urothelium and TCCs for Bcl-2 and p53. Immunohistochemical staining showed that Bcl-2 was expressed only on basal layer cells, whereas Bax expression was restricted to superficial layers in normal transitional epithelium. Benign lesions of the urinary bladder (Brunn's nests and inverted papillomas) showed strong immunoreactivity to Bcl-2. Taken together, 16 (17%) TCCs were positive for Bcl-2, 62 (64.6%) TCCs were positive for Bax and 28 (29%) TCCs were positive for p53. The expression of Bcl-2 on TCC had a statistical correlation with tumor stage, histopathologic grade and p53 protein accumulation. The results suggest that although Bcl-2 overexpression is detected in normal urothelium and benign lesions of the urinary bladder, it might also contribute to the high grade tumor malignancy of TCC.
doi_str_mv 10.1016/S0304-3835(98)00055-X
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79980234</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S030438359800055X</els_id><sourcerecordid>17128053</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-1a257e4725af3174cf45b691e3f15be1f93b3460f0f15e5415aba27d6c2a0ff33</originalsourceid><addsrcrecordid>eNqFkE1P3DAQhi0E2m63_QlIPiBEDyn-jJMTAlTaSkgcoBU3y3HGrCvHWeyk0v57sh-C45481jzz2vMgdErJd0poeflIOBEFr7i8qKtvhBApi-cjNKeVYoWqK3KM5u_IJ_Q5538bSCg5Q7O6lEzVao7u_prkTRMA39hQMLxaQuyH9Qqwj7iB6F8iNrHFnQlTaeKAA2Tfx4x7h8fUD0sIfuy-oBNnQoav-3OB_tz9eLr9Vdw__Px9e31fWMHIUFDDpAKhmDSOUyWsE7IpawrcUdkAdTVvuCiJI9MdpKDSNIaptrTMEOc4X6DzXe4q9a8j5EF3PlsIwUTox6xVPS3OuDgIUkVZReQmUe5Am_qcEzi9Sr4zaa0p0RvReitabyzqutJb0fp5mjvdPzA2HbTvU3uzU_9s3zfZmuCSidbnj_CSU8LIhF3tMJis_feQdLYeooXWJ7CDbnt_4CNvBYGZFA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17128053</pqid></control><display><type>article</type><title>Variable Bcl-2 phenotype in benign and malignant lesions of urothelium</title><source>Elsevier</source><creator>Bilim, Vladimir N ; Tomita, Yoshihiko ; Kawasaki, Takashi ; Takeda, Masayuki ; Takahashi, Kota</creator><creatorcontrib>Bilim, Vladimir N ; Tomita, Yoshihiko ; Kawasaki, Takashi ; Takeda, Masayuki ; Takahashi, Kota</creatorcontrib><description>We examined Bcl-2, Bax and p53 expression in transitional epithelium, benign lesions derived from transitional epithelium (Brunn's nests and inverted papillomas) and transitional cell cancer (TCC) of the upper urinary tract and urinary bladder using immunostaining of cryostat sections. We also performed Western blot analysis of normal urothelium and TCCs for Bcl-2 and p53. Immunohistochemical staining showed that Bcl-2 was expressed only on basal layer cells, whereas Bax expression was restricted to superficial layers in normal transitional epithelium. Benign lesions of the urinary bladder (Brunn's nests and inverted papillomas) showed strong immunoreactivity to Bcl-2. Taken together, 16 (17%) TCCs were positive for Bcl-2, 62 (64.6%) TCCs were positive for Bax and 28 (29%) TCCs were positive for p53. The expression of Bcl-2 on TCC had a statistical correlation with tumor stage, histopathologic grade and p53 protein accumulation. The results suggest that although Bcl-2 overexpression is detected in normal urothelium and benign lesions of the urinary bladder, it might also contribute to the high grade tumor malignancy of TCC.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/S0304-3835(98)00055-X</identifier><identifier>PMID: 9652797</identifier><identifier>CODEN: CALEDQ</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Adult ; Aged ; Apoptosis ; Bax ; Bcl-2 ; bcl-2-Associated X Protein ; Biological and medical sciences ; Carcinoma, Transitional Cell - genetics ; Carcinoma, Transitional Cell - metabolism ; Female ; Gene Expression ; Humans ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; p53 ; Proto-Oncogene Proteins - metabolism ; Proto-Oncogene Proteins c-bcl-2 - metabolism ; Transitional cell cancer ; Tumor Suppressor Protein p53 - metabolism ; Tumors of the urinary system ; Urinary Bladder Neoplasms - genetics ; Urinary Bladder Neoplasms - metabolism ; Urinary tract. Prostate gland ; Urogenital Neoplasms - metabolism ; Urothelium - metabolism</subject><ispartof>Cancer letters, 1998-06, Vol.128 (1), p.87-92</ispartof><rights>1998 Elsevier Science Ireland Ltd</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-1a257e4725af3174cf45b691e3f15be1f93b3460f0f15e5415aba27d6c2a0ff33</citedby><cites>FETCH-LOGICAL-c420t-1a257e4725af3174cf45b691e3f15be1f93b3460f0f15e5415aba27d6c2a0ff33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1631020$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9652797$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bilim, Vladimir N</creatorcontrib><creatorcontrib>Tomita, Yoshihiko</creatorcontrib><creatorcontrib>Kawasaki, Takashi</creatorcontrib><creatorcontrib>Takeda, Masayuki</creatorcontrib><creatorcontrib>Takahashi, Kota</creatorcontrib><title>Variable Bcl-2 phenotype in benign and malignant lesions of urothelium</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>We examined Bcl-2, Bax and p53 expression in transitional epithelium, benign lesions derived from transitional epithelium (Brunn's nests and inverted papillomas) and transitional cell cancer (TCC) of the upper urinary tract and urinary bladder using immunostaining of cryostat sections. We also performed Western blot analysis of normal urothelium and TCCs for Bcl-2 and p53. Immunohistochemical staining showed that Bcl-2 was expressed only on basal layer cells, whereas Bax expression was restricted to superficial layers in normal transitional epithelium. Benign lesions of the urinary bladder (Brunn's nests and inverted papillomas) showed strong immunoreactivity to Bcl-2. Taken together, 16 (17%) TCCs were positive for Bcl-2, 62 (64.6%) TCCs were positive for Bax and 28 (29%) TCCs were positive for p53. The expression of Bcl-2 on TCC had a statistical correlation with tumor stage, histopathologic grade and p53 protein accumulation. The results suggest that although Bcl-2 overexpression is detected in normal urothelium and benign lesions of the urinary bladder, it might also contribute to the high grade tumor malignancy of TCC.</description><subject>Adult</subject><subject>Aged</subject><subject>Apoptosis</subject><subject>Bax</subject><subject>Bcl-2</subject><subject>bcl-2-Associated X Protein</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Transitional Cell - genetics</subject><subject>Carcinoma, Transitional Cell - metabolism</subject><subject>Female</subject><subject>Gene Expression</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>p53</subject><subject>Proto-Oncogene Proteins - metabolism</subject><subject>Proto-Oncogene Proteins c-bcl-2 - metabolism</subject><subject>Transitional cell cancer</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><subject>Tumors of the urinary system</subject><subject>Urinary Bladder Neoplasms - genetics</subject><subject>Urinary Bladder Neoplasms - metabolism</subject><subject>Urinary tract. Prostate gland</subject><subject>Urogenital Neoplasms - metabolism</subject><subject>Urothelium - metabolism</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNqFkE1P3DAQhi0E2m63_QlIPiBEDyn-jJMTAlTaSkgcoBU3y3HGrCvHWeyk0v57sh-C45481jzz2vMgdErJd0poeflIOBEFr7i8qKtvhBApi-cjNKeVYoWqK3KM5u_IJ_Q5538bSCg5Q7O6lEzVao7u_prkTRMA39hQMLxaQuyH9Qqwj7iB6F8iNrHFnQlTaeKAA2Tfx4x7h8fUD0sIfuy-oBNnQoav-3OB_tz9eLr9Vdw__Px9e31fWMHIUFDDpAKhmDSOUyWsE7IpawrcUdkAdTVvuCiJI9MdpKDSNIaptrTMEOc4X6DzXe4q9a8j5EF3PlsIwUTox6xVPS3OuDgIUkVZReQmUe5Am_qcEzi9Sr4zaa0p0RvReitabyzqutJb0fp5mjvdPzA2HbTvU3uzU_9s3zfZmuCSidbnj_CSU8LIhF3tMJis_feQdLYeooXWJ7CDbnt_4CNvBYGZFA</recordid><startdate>19980605</startdate><enddate>19980605</enddate><creator>Bilim, Vladimir N</creator><creator>Tomita, Yoshihiko</creator><creator>Kawasaki, Takashi</creator><creator>Takeda, Masayuki</creator><creator>Takahashi, Kota</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19980605</creationdate><title>Variable Bcl-2 phenotype in benign and malignant lesions of urothelium</title><author>Bilim, Vladimir N ; Tomita, Yoshihiko ; Kawasaki, Takashi ; Takeda, Masayuki ; Takahashi, Kota</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-1a257e4725af3174cf45b691e3f15be1f93b3460f0f15e5415aba27d6c2a0ff33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Apoptosis</topic><topic>Bax</topic><topic>Bcl-2</topic><topic>bcl-2-Associated X Protein</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Transitional Cell - genetics</topic><topic>Carcinoma, Transitional Cell - metabolism</topic><topic>Female</topic><topic>Gene Expression</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>p53</topic><topic>Proto-Oncogene Proteins - metabolism</topic><topic>Proto-Oncogene Proteins c-bcl-2 - metabolism</topic><topic>Transitional cell cancer</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><topic>Tumors of the urinary system</topic><topic>Urinary Bladder Neoplasms - genetics</topic><topic>Urinary Bladder Neoplasms - metabolism</topic><topic>Urinary tract. Prostate gland</topic><topic>Urogenital Neoplasms - metabolism</topic><topic>Urothelium - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bilim, Vladimir N</creatorcontrib><creatorcontrib>Tomita, Yoshihiko</creatorcontrib><creatorcontrib>Kawasaki, Takashi</creatorcontrib><creatorcontrib>Takeda, Masayuki</creatorcontrib><creatorcontrib>Takahashi, Kota</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bilim, Vladimir N</au><au>Tomita, Yoshihiko</au><au>Kawasaki, Takashi</au><au>Takeda, Masayuki</au><au>Takahashi, Kota</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Variable Bcl-2 phenotype in benign and malignant lesions of urothelium</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>1998-06-05</date><risdate>1998</risdate><volume>128</volume><issue>1</issue><spage>87</spage><epage>92</epage><pages>87-92</pages><issn>0304-3835</issn><eissn>1872-7980</eissn><coden>CALEDQ</coden><abstract>We examined Bcl-2, Bax and p53 expression in transitional epithelium, benign lesions derived from transitional epithelium (Brunn's nests and inverted papillomas) and transitional cell cancer (TCC) of the upper urinary tract and urinary bladder using immunostaining of cryostat sections. We also performed Western blot analysis of normal urothelium and TCCs for Bcl-2 and p53. Immunohistochemical staining showed that Bcl-2 was expressed only on basal layer cells, whereas Bax expression was restricted to superficial layers in normal transitional epithelium. Benign lesions of the urinary bladder (Brunn's nests and inverted papillomas) showed strong immunoreactivity to Bcl-2. Taken together, 16 (17%) TCCs were positive for Bcl-2, 62 (64.6%) TCCs were positive for Bax and 28 (29%) TCCs were positive for p53. The expression of Bcl-2 on TCC had a statistical correlation with tumor stage, histopathologic grade and p53 protein accumulation. The results suggest that although Bcl-2 overexpression is detected in normal urothelium and benign lesions of the urinary bladder, it might also contribute to the high grade tumor malignancy of TCC.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>9652797</pmid><doi>10.1016/S0304-3835(98)00055-X</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0304-3835
ispartof Cancer letters, 1998-06, Vol.128 (1), p.87-92
issn 0304-3835
1872-7980
language eng
recordid cdi_proquest_miscellaneous_79980234
source Elsevier
subjects Adult
Aged
Apoptosis
Bax
Bcl-2
bcl-2-Associated X Protein
Biological and medical sciences
Carcinoma, Transitional Cell - genetics
Carcinoma, Transitional Cell - metabolism
Female
Gene Expression
Humans
Male
Medical sciences
Middle Aged
Nephrology. Urinary tract diseases
p53
Proto-Oncogene Proteins - metabolism
Proto-Oncogene Proteins c-bcl-2 - metabolism
Transitional cell cancer
Tumor Suppressor Protein p53 - metabolism
Tumors of the urinary system
Urinary Bladder Neoplasms - genetics
Urinary Bladder Neoplasms - metabolism
Urinary tract. Prostate gland
Urogenital Neoplasms - metabolism
Urothelium - metabolism
title Variable Bcl-2 phenotype in benign and malignant lesions of urothelium
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T07%3A19%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Variable%20Bcl-2%20phenotype%20in%20benign%20and%20malignant%20lesions%20of%20urothelium&rft.jtitle=Cancer%20letters&rft.au=Bilim,%20Vladimir%20N&rft.date=1998-06-05&rft.volume=128&rft.issue=1&rft.spage=87&rft.epage=92&rft.pages=87-92&rft.issn=0304-3835&rft.eissn=1872-7980&rft.coden=CALEDQ&rft_id=info:doi/10.1016/S0304-3835(98)00055-X&rft_dat=%3Cproquest_cross%3E17128053%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c420t-1a257e4725af3174cf45b691e3f15be1f93b3460f0f15e5415aba27d6c2a0ff33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=17128053&rft_id=info:pmid/9652797&rfr_iscdi=true